ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Why your retirement fund might soon include cryptocurrency 
Investors value green labels — but not always for the right reasons 
South Korea to End Short-Selling Ban as Financial Market Uncertainty Persists 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Mexico's Undervalued Equity Market Offers Long-Term Investment Potential 
Tech Stocks Rally in Asia-Pacific as Dollar Remains Resilient 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
Apple Downgraded by Jefferies Amid Weak iPhone Sales and AI Concerns 
easyJet Agrees in Principle to £5.23 Billion Castlelake Takeover Offer 
U.S. Banks Report Strong Q4 Profits Amid Investment Banking Surge 
AI Memory Chip Shortage Likely to Persist Despite Korea Investment Boom, Nomura Says 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
